Discovery Eye Foundation
  • Decrease font size
  • Default font           size
  • Increase font size
Current Newsletter
Cholesterol and AMD Print E-mail

High cholesterol is often cited as a contributing factor to age-related macular degeneration.  Many studies have shown an association between AMD and serum lipids.  People with high cholesterol often take statin medication to reduce the cholesterol level.  Some studies have even shown an association between statin drugs and a reduction in the occurrence of AMD.  The evidence is confusing.

Blood Pressure and AMD Print E-mail

Recently, the news was full of headlines about blood pressure medication that may be associated with an increased risk for early development of age-related macular degeneration.  As is often the case with bold headlines, the rest of the story is more complicated.  The data was from the Beaver Dam Eye Study, a long term population study from Beaver Dam, Wisconsin, involving almost 5,000 people over a 20 year period.  Of these, 1913 are still in the study.  It may be important to note that 99% of the participants are white.

Those participants who are taking vasodilator medication for high blood pressure had a 72% higher risk of developing early AMD.

Radiation - Brachytherapy for Wet AMD Print E-mail

Two-year clinical trial data was just released for epimacular brachytherapy, a radiation treatment for wet AMD.   The MERITAGE trial involves 53 patients who had previously been treated with Lucentis and who had required monthly injections to control blood vessel growth.   Individuals in the study received a single treatment with epimacular brachytherapy, a unique radiation delivery system .  Over three years, the participants are then treated as needed with Lucentis.

Interim Results of AMD Eye Drops Research Print E-mail
As promised in April, Ohr Pharmaceutical, Inc. has provided  interim results for the Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). This study compared the use of Squalamine eye drops in combination with Lucentis treatment versus a placebo eye drop and Lucentis treatment.  The visual acuity improvements were seen as early as four weeks and the relative difference in visual acuity between the two treatment arms continued to increase throughout the study.
Financial Aid for AMD Injections Print E-mail

The standard treatment is for wet macular degeneration involves repeated injections into the eye.  These can be very expensive, especially for someone without a secondary insurance.  Lucentis and Eylea cost around $2000 per injection.  The financial burden can be overwhelming.

The Patient Access Network (PAN) Foundation is dedicated to providing help and hope to underinsured patients who would otherwise be unable to afford high-cost specialty medications.





Get News!


To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:

For Email Newsletters you can trust

Tell us...

Please tell us about yourself: